• Blog
  • Glaucoma Treatment Market Growth Analysis | 2023-28

    Glaucoma Treatment Market Growth Analysis | 2023-28

    Glaucoma Treatment Market Growth Analysis | 2023-28
    Report code - SRHL292 Delivery - 2 Weeks
    Glaucoma Treatment Market, Dynamics, Forcast, Trend & Competitive Analysis | 2023-28
    See more...

    Market Insights

    The glaucoma treatment market is estimated to grow from USD 6.13 billion in 2022 to USD 7.46 billion by 2028 at a CAGR of 3.24% during the forecast period.

    To get detailed information about this report, Click here.

    What is Glaucoma?

    Glaucoma is primarily referred to as a silent thief of sight, as most of its types typically exhibit no symptoms, no pain until noticeable vision loss occurs. It is a group of related eye disorders that occurs mainly due to damage to the optic nerve which carries information from the eye to the brain. In most cases, associated with ocular hypertension, a condition when the pressure inside the eye is higher than normal pressure but sometimes it can occur when the intraocular pressure is normal.

    Global Glaucoma Treatment Market Report Overview

    Market Size in 2028

    USD 7.46 billion

    Market Size in 2022

    USD 6.13 billion

    Market Growth (2023-2028)

    CAGR of 3.24%

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2022-2028

    Key Players

    Key players operating in the glaucoma treatment market are-

    • Merck & Co., Inc. (The U.S),
    • Novartis AG (Switzerland),
    • Allergan Plc (The U.S),
    • AERIE PHARMACEUTICALS, INC. (The U.S),
    • Bausch & Lomb Incorporated (The U.S),
    • Akorn, Incorporated (The U.S),
    • Pfizer Inc (The U.S),
    • Inotek Pharmaceuticals (The U.S), and
    • Santen Pharmaceutical Co., Ltd.(Japan).

    Market Dynamics

    Rising cases of glaucoma are a key factor boosting the demand for glaucoma treatment market across the globe.

    • As glaucoma is a painless disorder of the eye that does not exhibit any kind of symptoms until significant vision loss, several patients suffering from glaucoma are rising day by day.
    • In addition, rising awareness of the glaucoma treatment market through pharmaceutical and government companies’ campaigns is further creating lucrative growth opportunities for the market players.
    • Furthermore, significant technological developments in treatment as eye drops are the primary control sage for glaucoma, and various pharmaceutical and biotechnological companies are investing in new product development for glaucoma is another reason behind the  market growth.

    To know more about the market trends, Register here.

    COVID-19 Impact On Glaucoma Treatment Market

    The ongoing COVID-19 pandemic has significantly affected the glaucoma treatment industry due to the shift of medical treatment from glaucoma and other health conditions towards the treatment of coronavirus-affected patients. Many government healthcare facilities have recognized glaucoma as an elective. Thus, all the surgeries associated with this condition were postponed or canceled across the globe due to the outbreak of the COVID-19 pandemic.

    Segment Analysis

    Glaucoma Treatment Market: By Drug Class Trends

    The market has been categorized into prostaglandin analogs, beta-blockers, alpha agonists, carbonic anhydrase inhibitors, and others.

    • Among these, the prostaglandin analogs segment held more than 31% of the share in 2022.
    • This is mainly attributed to the growing number of geriatric patients with glaucoma and prostaglandin analogs are administered as an eye drop, thus ease of using the drug is likely to augment the growth of prostaglandin analogs.

    Glaucoma Treatment Market: Regional Trends

    North America held more than 3.5% CAGR during the forecast period.

    • This can be attributed to rising healthcare expenditure, the presence of major healthcare companies, and the increasing senior population, promulgating the product region in the region.
    • Moreover, growing cases of glaucoma in the region coupled with better healthcare infrastructure further boost regional growth.

    To know which region offers the best opportunities, Click here

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

    We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence most comprehensively. The glaucoma treatment market report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market. 

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Global Glaucoma Treatment Market

    How lucrative is the future?

    The market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market Segment Analysis and Forecast

    What are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirements?

    10% free customization

    Target Audience

    The following is a list of the customers that the glaucoma treatment market aims to convert the most:

    • Glaucoma treatment companies
    • Hospitals
    • Diagnostic centers and laboratories
    • Academic Institutions
    • Research centers & organizations

    Critical Questions Answered in the Report

    • What are the key trends in the global glaucoma treatment market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global glaucoma treatment market?
    • What are the key strategies adopted by the major vendors to lead in the global glaucoma treatment market?
    • What is the market share of the top vendors?

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Glaucoma is primarily referred to as a silent thief of sight, as most of its types typically exhibit no symptoms, no pain until noticeable vision loss occurs. It is a group of related eye disorders which occurs mainly due to damage to the optic nerve which carries information from the eye to the brain. In most cases, associated with ocular hypertension, a condition when the pressure inside the eye is higher than normal pressure but sometimes it can occur when the intraocular pressure is normal.

    Merck & Co., Inc. (The U.S), Novartis AG (Switzerland), Allergan Plc (The U.S), AERIE PHARMACEUTICALS, INC. (The U.S), Bausch & Lomb Incorporated (The U.S), Akorn, Incorporated (The U.S), Pfizer Inc (The U.S), Inotek Pharmaceuticals (The U.S) and Santen Pharmaceutical Co., Ltd.(Japan) are among the key players in the market.

    North America witnessed the largest share of the market in 2022.

    Rising cases of glaucoma, rising awareness of glaucoma by pharmaceutical and government companies campaigns, and significant technological developments are the factors driving the growth of market.

    The prostaglandin analogs segment is expected to register a healthy CAGR in the market during the forecast period.

    Glaucoma treatment companies, Hospitals, Diagnostic centers and laboratories, Academic Institutions, Research centers & organizations are the glaucoma treatment market.

    The market is likely to grow from USD 6.13 billion in 2021 to reach USD 7.46 billion by 2028.

    The market is likely to grow at a healthy CAGR of 3.24% during the forecast period.